Inozyme Pharma Statistics

Total Valuation

Inozyme Pharma has a market cap or net worth of $192.08 million. The enterprise value is $107.26 million.

Market Cap	192.08M
Enterprise Value	107.26M

Important Dates

The last earnings date was Tuesday, November 5, 2024, before market open.

Earnings Date	Nov 5, 2024
Ex-Dividend Date	n/a

Share Statistics

Inozyme Pharma has 64.24 million shares outstanding. The number of shares has increased by 31.49% in one year.

Current Share Class	64.24M
Shares Outstanding	64.24M
Shares Change (YoY)	+31.49%
Shares Change (QoQ)	+2.15%
Owned by Insiders (%)	0.50%
Owned by Institutions (%)	47.27%
Float	32.59M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.32
P/TBV Ratio	2.32
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.68, with a Debt / Equity ratio of 0.57.

Current Ratio	7.68
Quick Ratio	7.17
Debt / Equity	0.57
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-18.40

Financial Efficiency

Return on equity (ROE) is -79.42% and return on invested capital (ROIC) is -38.46%.

Return on Equity (ROE)	-79.42%
Return on Assets (ROA)	-35.69%
Return on Capital (ROIC)	-38.46%
Revenue Per Employee	n/a
Profits Per Employee	-$1.64M
Employee Count	59
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -28.81% in the last 52 weeks. The beta is 1.37, so Inozyme Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.37
52-Week Price Change	-28.81%
50-Day Moving Average	3.70
200-Day Moving Average	4.78
Relative Strength Index (RSI)	46.60
Average Volume (20 Days)	920,473

Short Selling Information

The latest short interest is 3.41 million, so 5.30% of the outstanding shares have been sold short.

Short Interest	3.41M
Short Previous Month	3.31M
Short % of Shares Out	5.30%
Short % of Float	10.45%
Short Ratio (days to cover)	7.59

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-99.67M
Pretax Income	-88.56M
Net Income	-96.49M
EBITDA	-98.89M
EBIT	-99.67M
Earnings Per Share (EPS)	-$1.55

Full Income Statement

Balance Sheet

The company has $131.61 million in cash and $46.79 million in debt, giving a net cash position of $84.82 million or $1.32 per share.

Cash & Cash Equivalents	131.61M
Total Debt	46.79M
Net Cash	84.82M
Net Cash Per Share	$1.32
Equity (Book Value)	82.79M
Book Value Per Share	1.29
Working Capital	122.59M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$91.21 million and capital expenditures -$150,000, giving a free cash flow of -$91.36 million.

Operating Cash Flow	-91.21M
Capital Expenditures	-150,000
Free Cash Flow	-91.36M
FCF Per Share	-$1.42

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Inozyme Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-31.49%
Shareholder Yield	-31.49%
Earnings Yield	-50.24%
FCF Yield	-47.56%

Analyst Forecast

The average price target for Inozyme Pharma is $16.14, which is 439.80% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$16.14
Price Target Difference	439.80%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1